ALGS insider transaction filings
Aligos Therapeutics, Inc. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-29. Screen ALGS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Chavez Margarita — Director | 1 | — | — | 1 |
| Hirth Peter — Director | 1 | — | — | 1 |
| Martell Bridget A — Director | 1 | — | — | 1 |
| Nuechterlein Carole — Director | 1 | — | — | 1 |
| Preston Heather — Director | 1 | — | — | 1 |
| Scopa James Paul — Director | 1 | — | — | 1 |
Recent Form 4 filings — Aligos Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Chavez Margarita — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Hirth Peter — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Nuechterlein Carole — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Martell Bridget A — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Preston Heather — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Scopa James Paul — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Symons Julian A. — See Remarks | Grant/award (A): 23,310 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Aneja Nikhil — Principal Accounting Officer | Grant/award (A): 9,450 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Calhoun Lesley Ann — See Remarks | Grant/award (A): 37,485 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | BLATT LAWRENCE — President and CEO, Director | Grant/award (A): 105,840 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Symons Julian A. — See Remarks | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | Calhoun Lesley Ann — See Remarks | Grant/award (A): 40,185 (derivative) @ $0 | EDGAR |
| 2025-07-18 | 4 | BLATT LAWRENCE — President and CEO, Director | Grant/award (A): 179,800 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Hirth Peter — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Chavez Margarita — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Nuechterlein Carole — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Martell Bridget A — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Preston Heather — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Scopa James Paul — Director | Grant/award (A): 5,860 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Symons Julian A. — See Remarks | Grant/award (A): 21,693 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Calhoun Lesley Ann — See Remarks | Grant/award (A): 47,271 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | BLATT LAWRENCE — President and CEO, Director | Grant/award (A): 140,103 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | Achneck Hardean — Chief Medical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-09-06 | 4 | Symons Julian A. — See Remarks | Grant/award (A): 10,880 (derivative) @ $0 | EDGAR |
| 2024-09-06 | 4 | Calhoun Lesley Ann | Grant/award (A): 10,880 (derivative) @ $0 | EDGAR |
| 2024-09-06 | 4 | BLATT LAWRENCE — Chief Executive Officer, Director | Grant/award (A): 33,920 (derivative) @ $0 | EDGAR |
| 2024-08-09 | 4 | Chavez Margarita — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-08-09 | 4 | Preston Heather — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Hirth Peter — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Nuechterlein Carole — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Martell Bridget A — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Scopa James Paul — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | McClure Matthew W. — Chief Medical Officer | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Symons Julian A. — See Remarks | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Calhoun Lesley Ann | Grant/award (A): 308,940 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | BLATT LAWRENCE — Chief Executive Officer, Director | Grant/award (A): 965,435 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Hirth Peter — Director | Disposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 4,411 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | McClure Matthew W. — Chief Medical Officer | Disposition to issuer (D): 255,626 (derivative) @ $0 · Disposition to issuer (D): 92,000 (derivative) @ $0 · Disposition to issuer (D): 23,000 (derivative) @ $0 · Grant/award (A): 75,183 (derivative) @ $0 · Grant/award (A): 65,713 (derivative) @ $0 · Grant/award (A): 16,428 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Symons Julian A. — See Remarks | Disposition to issuer (D): 200,000 (derivative) @ $0 · Disposition to issuer (D): 105,000 (derivative) @ $0 · Disposition to issuer (D): 26,250 (derivative) @ $0 · Grant/award (A): 58,822 (derivative) @ $0 · Grant/award (A): 74,998 (derivative) @ $0 · Grant/award (A): 18,750 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Calhoun Lesley Ann | Disposition to issuer (D): 176,237 (derivative) @ $0 · Disposition to issuer (D): 105,000 (derivative) @ $0 · Disposition to issuer (D): 26,250 (derivative) @ $0 · Grant/award (A): 51,833 (derivative) @ $0 · Grant/award (A): 74,998 (derivative) @ $0 · Grant/award (A): 18,750 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Nuechterlein Carole — Director | Disposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 4,411 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Martell Bridget A — Director | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 8,823 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Nielsen Jack — Director | Disposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 4,411 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | Scopa James Paul — Director | Disposition to issuer (D): 30,000 (derivative) @ $0 · Grant/award (A): 8,823 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | BLATT LAWRENCE — Chief Executive Officer, Director | Disposition to issuer (D): 450,000 (derivative) @ $0 · Disposition to issuer (D): 323,400 (derivative) @ $0 · Disposition to issuer (D): 80,850 (derivative) @ $0 · Grant/award (A): 132,352 (derivative) @ $0 · Grant/award (A): 230,999 (derivative) @ $0 · Grant/award (A): 57,749 (derivative) @ $0 | EDGAR |
Recent 8-K events — Aligos Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-04-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ALGS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →